TBC1D12

Across TCGA pan-cancer cohorts, TBC1D12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBC1D12 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TBC1D12 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated TBC1D12 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, COAD, and PRAD are the cancer types where TBC1D12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	0.741	0.578	.010	12	view →
COAD	DFS	Median	All	0.186	0.694	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.631	.032	4	view →
THCA	DFS	Median	All	0.275	0.848	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBC1D12–BLCA (OS)

Open the BLCA breakdown →